Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Multimodality Treatment for Patients with Node-Positive Prostate Cancer: the Role of Radiation Therapy

  • Ochiai, Satoru (Department of Radiation Oncology, Matsusaka Central Hospital) ;
  • Nomoto, Yoshihito (Department of Radiology, Mie University School of Medicine) ;
  • Kobayashi, Shigeki (Department of Radiology, Mie University School of Medicine) ;
  • Yamashita, Yasufumi (Department of Radiation Oncology, Matsusaka Central Hospital) ;
  • Watanabe, Yui (Department of Radiology, Mie University School of Medicine) ;
  • Toyomasu, Yutaka (Department of Radiology, Mie University School of Medicine) ;
  • Kawamura, Tomoko (Department of Radiology, Mie University School of Medicine) ;
  • Takada, Akinori (Department of Radiology, Mie University School of Medicine) ;
  • II, Noriko (Department of Radiology, Mie University School of Medicine) ;
  • Sakuma, Hajime (Department of Radiology, Mie University School of Medicine)
  • Published : 2016.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Prostate cancer is the secondary most frequently diagnosed cancer in the world. Although numerous prospective randomized trial have been conducted to guide the management of patients with localized or locally advanced prostate cancer, few clinical trials targeting node-positive prostate cancer have been reported. Therefore, there are still controversies in the optimal management of node-positive prostate cancer. Recently, efficacy of multimodality treatment, including radiation therapy (RT), for such patients has been reported in several articles. The results indicate potential benefit of RT both in adjuvant therapy after prostatectomy and in definitive therapy for node-positive prostate cancer. The aim in this article was to summarize the current evidence for RT and evaluate the role in multimodality treatment for patients with node-positive prostate cancer.

Keywords

References

  1. Abdollah F, Karnes RJ, Suardi N, et al (2014). Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol, 65, 554-62. https://doi.org/10.1016/j.eururo.2013.09.025
  2. Abdollah F, Karnes RJ, Suardi N, et al (2014). Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol, 32, 3939-47. https://doi.org/10.1200/JCO.2013.54.7893
  3. Baker BR, Mohiuddin JJ, Chen RC (2015). The role of radiotherapy in node-positive prostate cancer. Oncol (Williston Park), 29, 108-16.
  4. Blanchard P, Faivre L, Lesaunier F, et al (2015). Outcome according to elective pelvic radiation therapy in patients with high-risk localized prostate cancer: a secondary analysis of the GETUG 12 Phase 3 Randomized Trial. Int J Radiat Oncol Biol Phys, [Epub ahead of print].
  5. Briganti A, Blute ML, Eastham JH, et al (2009). Pelvic lymph node dissection in prostate cancer. Eur Urol, 55, 1251-65. https://doi.org/10.1016/j.eururo.2009.03.012
  6. Briganti A, Capitanio U, Chun FK, et al (2008). Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol, 54, 794-802. https://doi.org/10.1016/j.eururo.2008.05.018
  7. Briganti A, Karnes RJ, Da Pozzo LF, et al (2011). Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol, 59, 832-40. https://doi.org/10.1016/j.eururo.2011.02.024
  8. Crehange G, Chen CP, Hsu CC, et al (2012). Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev, 38, 956-67. https://doi.org/10.1016/j.ctrv.2012.05.005
  9. Da Pozzo LF, Cozzarini C, Briganti A, et al (2009). Longterm follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol, 55, 1003-11. https://doi.org/10.1016/j.eururo.2009.01.046
  10. Fizazi K, Faivre L, Lesaunier F, et al (2015). Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol, 16, 787-94. https://doi.org/10.1016/S1470-2045(15)00011-X
  11. Fonteyne V, Lumen N, Ost P, et al (2013). Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome. Radiother Oncol, 109, 229-34. https://doi.org/10.1016/j.radonc.2013.08.006
  12. Iversen P, Wirth MP, See WA, et al (2004). Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (casodex) early prostate cancer program. Urol, 63, 928-33. https://doi.org/10.1016/j.urology.2004.02.011
  13. James ND, Spears MR, Clarke NW, et al (2015). Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial. JAMA Oncol. [Epub ahead of print].
  14. Kunath F, Keck B, Rücker G, et al (2013). Early versus deferred androgen suppression therapy for patients with lymph nodepositive prostatecancer after local therapy with curative intent: a systematic review. BMC Cancer, 13, 131. https://doi.org/10.1186/1471-2407-13-131
  15. Lawton CA, Winter K, Byhardt R, et al (1997). Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 38, 931-9. https://doi.org/10.1016/S0360-3016(97)00288-5
  16. Lawton CA, Winter K, Grignon D, et al (2005). Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol, 23, 800-7. https://doi.org/10.1200/JCO.2005.08.141
  17. Lilleby W, Narrang A, Tafjord G, et al (2015). Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Radiat Oncol, 10, 232. https://doi.org/10.1186/s13014-015-0540-3
  18. Lin CC, Gray PJ, Jemal A, et al (2015). Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst, 107, 119. https://doi.org/10.1093/jnci/djv119
  19. Messing EM, Manola J, Sarosdy M, et al (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341, 1781-8. https://doi.org/10.1056/NEJM199912093412401
  20. Messing EM, Manola J, Yao J, et al (2006). Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol, 7, 472-9. https://doi.org/10.1016/S1470-2045(06)70700-8
  21. Mizowaki T, Inokuchi H, Nakamura K, et al (2015). Outcomes of high-dose whole-pelvic IMRT with simultaneous integrated boost in patients with pelvic lymph node-positive prostate Cancer. Int J Radiat Oncolo Biol Phys, 93, 188.
  22. Rusthoven CG, Carlson JA, Waxweiler TV, et al (2014). The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys, 88, 1064-73. https://doi.org/10.1016/j.ijrobp.2014.01.008
  23. Schroder FH, Kurth KH, Fossa SD, et al (2004). Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of european organisation for the research and treatment of Cancer 30846--a phase III study. J Urol, 172, 923-7. https://doi.org/10.1097/01.ju.0000135742.13171.d2
  24. Schroder FH, Kurth KH, Fossa SD, et al (2009). Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of european organisation for the research and treatment of cancer protocol 30846 after 13 years of followup (a randomised controlled trial). Eur Urol, 55, 14-22. https://doi.org/10.1016/j.eururo.2008.09.008
  25. Swanson GP, Thompson IM, Basler J (2006). Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer, 107, 439-50. https://doi.org/10.1002/cncr.22034
  26. Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87-108. https://doi.org/10.3322/caac.21262
  27. Sydes MR, Parmar MK, Mason MD, et al (2012). Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials, 13, 168. https://doi.org/10.1186/1745-6215-13-168
  28. Tward JD, Kokeny KE, Shrieve DC (2013). Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol, 3, 234-40. https://doi.org/10.1016/j.prro.2012.11.011
  29. Zagars GK, Pollack A, von Eschenbach AC (2001). Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urol, 58, 233-9. https://doi.org/10.1016/S0090-4295(01)01168-2

Cited by

  1. Nontoxic Glucomoringin-Isothiocyanate (GMG-ITC) Rich Soluble Extract Induces Apoptosis and Inhibits Proliferation of Human Prostate Adenocarcinoma Cells (PC-3) vol.10, pp.9, 2018, https://doi.org/10.3390/nu10091174